Pharmaceutical Analysis
Our large, experienced inhalation group of analytical scientists can undertake the comprehensive array of test methodologies and physical properties characterization required to support the development of inhaled products.
With extensive, state-of-the-art analytical testing facilities and equipment, our expert teams are able to develop and validate the methodologies required to characterize inhaled delivery platforms, especially DPI, pMDI and nebulized products.
To ensure seamless support, we also offer:
- Comprehensive stability storage facilities to support small bespoke stability studies and large pivotal programs
- Deep experience of developing pharmaceutics, device verification testing and authoring CMC sections for regulatory submissions
Our comprehensive analytical services include:
- Conventional chromatography and aerosol characterization using HPLC, UPLC, GC, cascade impaction, delivered dose analysis and spray-pattern testing
- LC detection capabilities include UV and UV diode array, fluorescence, refractive index, charged aerosol detection (CAD) and mass spectroscopy
- Physico-chemical (Q3 type) methods capability, including more realistic testing using throat models and patient inhalation profiles, and dissolution profiling and blend microstructure measurements, which are key to understanding equivalence for generic programs or bridging between devices and formulations
- Dedicated physical properties capability, including Morphologi 4-ID automated particle size/shape analysis and surface properties measurement, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM)
- Biologics evaluation methodologies, including SDS-PAGE electrophoresis, plate-based assays, isoelectric focusing, dynamic light scattering and zeta potential
- Solution physico-chemical properties measurements for liquid formulations (rheometry, viscometry, osmolality, surface tension)
Featured Resources
Publication
ODD: Integrating Phillips Medisize and Vectura’s Operations
In this interview, Phillips Medisize’s Charlie Schumacher and Sandy Munro discuss the company’s progress on its integration of Vectura. Learn more.
Publication
ODD: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson of Phillips Medisize discuss the company’s expanded capabilities as a result of its recent acquisition of Vectura. Learn more.
Publication
PMPS: Elevate Your Molecule
Phillips Medisize’s 2025 acquisition of Vectura expanded its offerings to include inhaled drug development for small molecules, biologics and complex combinations for both novel and generic products. Learn more.